Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andexanet Alfa vs Usual Care in Urgent Surgery (ANNEXA-RS)
NCT05926349Phase 3Withdrawn
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Primary completion
- Jan 2027
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of andexanet alfa in hemorrhage, sponsored by AstraZeneca. Planned start Aug 2024; status: withdrawn.
02
Drugs
andexanet alfa
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT05926349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05926349.